ALC Shares Alcidion Group Limited
ASX · ASXLast in our picks 2026-10-10 — not in the current list; analysis below is from that screen
Healthcare software platform can leverage AI-assisted clinical workflows and recurring digital-health demand.
Future value: $0.15 (+49.09%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Healthcare AI optionality, but financial performance and liquidity remain challenging.
- ▸Above 50-day MA (+1.39%)
- ▸Volume 1.65× average — accumulation
- ▸~49% upside to price target
Is ALC a buy right now?
Trend: ALC is trading above the 50-day average (+0.00%), RSI 42 — neutral momentum, with a 3-month return of +12.36%.
Valuation & quality: Alcidion Group Limited trades on forward P/E 30.1, price-to-book 1.47; fundamentals show net margin 4.4%, return on equity 2.6%, revenue growth 13.1% year on year.
Analyst consensus: 5 analysts have a mean 12-month price target of A$0.15 (+47.6% vs the last close; range A$0.13 – A$0.17), consensus rating “none”.
Our screen: BUY (score 3) — Healthcare software platform can leverage AI-assisted clinical workflows and recurring digital-health demand.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +10.00% | -9.10% | -10.00% | +11.10% | +10.00% | -9.10% |
Fundamentals
Analyst price target
Technical signals
About Alcidion Group Limited
Alcidion Group Limited, together with its subsidiaries, develops and sells digital health software solutions for healthcare organisations in Australia, New Zealand, and the United Kingdom.
Sector: Healthcare · Industry: Health Information Services · Australia · 141 employees · Website
Related Artificial Intelligence picks
Browse: all ASX stocks · Artificial Intelligence picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.